Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4202L
ReNeuron Group plc
12 August 2013
 

 

DTR3

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

 

(i)

 

3.

Name of person discharging managerial responsibilities/director

 

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

 

Director named in 3.

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

 

Interest of person named in 3

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

Ordinary Shares

 

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

Person named in 3

 

8.

State the nature of the transaction

 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

 

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

 

0.011%

 

11.

Number of shares, debentures or financial instruments relating to shares disposed

 

 

 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

 

 

13.

Price per share or value of transaction

 

2.5 pence per Ordinary Share

 

14.

Date and place of transaction

 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

 

16.

Date issuer informed of transaction

 

9 August 2013

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

 

17.

Date of grant

 

 

18.

Period during which or date on which it can be exercised

 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

 

See table of options held by Dr. Paul Harper below:

 

 

 

Number of options

Exercise Price

End of Exercise Period

98,781

12.65p

August 2015

98,688

5.07p

August 2016

258,098

12.2p

August 2017

226,682

4.85p

August 2019

277,797

4.43p

August 2020

417,274

4.31p

August 2021

500,000

3.3pp

August 2022

1,877,300

24.

Name of contact and telephone number for queries

 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

 

 

Name of authorised official of issuer responsible for making notification:

 

Patrick Huggins, Head of Finance and Company Secretary

 

Date of notification: 9 August 2013

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEETIIAIIV
Date   Source Headline
8th Oct 201010:26 amRNS18th Annual BioPartnering Europe conference
8th Sep 201011:07 amRNSResults of 2010 Annual General Meeting
8th Sep 20107:00 amRNS2010 AGM Trading Update
9th Aug 20107:00 amRNSPosting of Report and Accounts and AGM date
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
15th Jul 20107:00 amRNSNotification of Investor Evening
12th Jul 20107:00 amRNSResult of pre-clinical studies
29th Jun 20107:00 amRNSPreliminary Results
17th Jun 20107:00 amRNSPreliminary Results Notification
13th May 20102:38 pmRNSBlock listing application
29th Apr 20107:00 amRNSNew positive data to be presented at US conference
1st Apr 20109:58 amRNSHolding in Company
31st Mar 20104:35 pmRNSHolding(s) in Company
22nd Mar 201010:44 amRNSReNeuron cited as UK regenerative medicine leader
18th Mar 20107:00 amRNSReNeuron signs further manufacturing contracts
15th Mar 20102:44 pmRNSSecond Closing of the Placing
12th Mar 201012:18 pmRNSResult of General Meeting
3rd Mar 20107:00 amRNSReNeuron presents pre-clinical efficacy data
22nd Feb 20107:00 amRNSReNeuron Announces Fundraising
18th Feb 20107:00 amRNSRetinal Stem Cell Research Grant
10th Feb 20107:00 amRNSFinal Approval Received To Commence Stroke Trial
8th Feb 201012:55 pmRNSIssue of Ordinary Shares
1st Feb 20107:00 amRNSClinical Advisory Board appointments
28th Jan 20107:00 amRNSRegulatory update
27th Jan 201011:42 amRNSReNeuron welcomes "Life Sciences 2010" report
1st Dec 20097:00 amRNSIssue of Ordinary Shares
27th Nov 20097:00 amRNSTwo grants awarded by regenerative funding program
26th Nov 20097:02 amRNS?5 million equity funding facility secured
26th Nov 20097:00 amRNSHalf Yearly Report
23rd Nov 20097:00 amRNSNotice of Results
16th Nov 20097:00 amRNSPositive data presented at leading US conference
22nd Oct 20091:49 pmRNSReNeuron to present at Royal Society of Medicine
2nd Oct 20097:00 amRNSPublication of new research using ReNcell
17th Sep 200910:47 amRNSResult of AGM
17th Sep 20097:00 amRNSAGM Statement
14th Sep 20097:02 amRNSTrading Platform
14th Sep 20097:00 amRNSChange of Adviser
10th Sep 20097:00 amRNSAngel and Reneuron announce contract
10th Sep 20097:00 amRNSRe Agreement
9th Sep 20095:00 pmRNSHolding(s) in Company
12th Aug 20097:00 amRNSDirector/PDMR Shareholding
11th Aug 20097:00 amRNSPublication of papers in peer-reviewed journals
10th Aug 20099:28 amRNSPublication of pre-clinical data
31st Jul 200911:21 amRNS2008/09 Annual Report and Accounts
30th Jul 200910:05 amRNSRegulatory Update
14th Jul 20093:48 pmRNSLaunch of "Life Sciences Blueprint"
8th Jul 20099:33 amRNSPublication of data on lead CTX stem cell line
30th Jun 20097:00 amRNSFinal Results
29th Jun 20093:44 pmRNSHolding(s) in Company
24th Jun 200910:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.